This study identified SV2B as an efficient biomarker for TFE3‐RCC and highlighted the role of the TFE3‐SV2B‐NF‐κB axis in TFE3‐RCC progression, providing new clinical diagnostic and treatment strategies for the disease. This evidence concerns the gene SV2B and renal cell carcinoma.